The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2014: Volume 19/ Issue 24 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 19, Issue 24, 19 June 2014
Rapid communications
Imported toxigenic cutaneous diphtheria in a young male returning from Mozambique to Norway, March 2014
  1. Department of Medical microbiology, St. Olavs University Hospital, Trondheim, Norway
  2. Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway
  3. Department of Infectious Diseases Control, Municipality of Trondheim, Norway
  4. Department of Infectious Diseases, St. Olavs University Hospital, Trondheim, Norway
  5. Sørbyen Legesenter, Heimdal, Norway
  6. Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway

Citation style for this article: Jakovljev A, Steinbakk M, Mengshoel AT, Sagvik E, Brügger-Synnes P, Sakshaug T, Rønning K, Blystad H, Bergh K. Imported toxigenic cutaneous diphtheria in a young male returning from Mozambique to Norway, March 2014 . Euro Surveill. 2014;19(24):pii=20835. Article DOI:
Date of submission: 19 May 2014

In March 2014 a 20-year-old man was diagnosed with cutaneous diphtheria at St. Olavs University Hospital in Trondheim, Norway on his return from Africa. The man had been in Mozambique since autumn 2013 and had experienced persistent skin ulcer infections. His was in good general health. Toxin-producing Corynebacterium diphtheriae was grown from a wound specimen. He had completed the national childhood vaccination programme and received a diphtheria vaccine booster dose in 2005. Screening of close contacts revealed an asymptomatic person colonised with non-toxigenic C. diphtheriae.

Case report and laboratory diagnosis

On 23 March 2014, one week after his arrival from Mozambique to Norway, a 20-year-old man presented at the Municipal Emergency Department in Trondheim with a history of skin ulcer, located on the right big toe that had lasted since approximately five to six weeks. He had been working in an orphanage in Mozambique with three other schoolmates from Norway since autumn in the previous year. The patient recalled having had similar leg ulcers lasting for several weeks from October 2013, acquired after his arrival at the orphanage. He could remember some insect bites, as well as minor trauma after he had played football in open toe sandals during his stay there. These ulcers healed after he had received amoxicillin/clavulanic-acid orally for one week, prescribed by a local physician in Mozambique.

At the Emergency Department in Trondheim, the examining physician suspected an infection caused by pyogenic bacteria and a wound specimen was requested for aerobic culture and screening for meticillin-resistant Staphylococcus aureus (MRSA). A treatment consisting of oral dicloxacillin tablets 500 mg four times daily was initiated.   

After 24 hours of incubation on blood agar and chocolate agar, abundant growth of almost pure culture of small, 1–2 mm in diameter, white, non-haemolytic colonies mimicking normal bacterial skin flora, was observed. A wet mount demonstrated short rods. Using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) on a Microflex LT mass spectrometer (Bruker Daltonics) with BioTyper 3.2 software database, the isolate was identified as Corynebacterium diphtheriae. Score values of 2.113 and 2.041 were interpreted as reliable species identification, as recommended by the manufacturer.

On Tinsdale selective medium (Tinsdale agar base: Difco product nr.278610 and Tinsdale enrichment Difco product nr.234210, BD Diagnostics – Diagnostic Systems), the isolate displayed characteristic deep brown colonies with halos after 24 hours of incubation. 

Laboratory investigation at the National Reference Laboratory
On 26 March the isolate was sent on Amies transport medium to the National Reference Laboratory for Diphtheria at the Norwegian Institute of Public Health (NIPH), Oslo, and diphtheria toxin tox gene was detected by polymerase chain reaction (PCR) [1] on 28 March. Diphtheria toxin production was analysed by modified Elek test [2] and reported positive on 29 March. The strain was identified as C. diphtheriae biotype mitis by API Coryne v3 system (BioMérieux, France, code: 1010364) and supplementary tests (nitrate reduction positive, glycogen fermentation positive, not lipophilic and forming large colonies (>1 mm in diameter after 24 hours of incubation)).

Minimum Inhibitory Concentration (MIC) for benzylpenicillin was 0.125 mg/L determined by Epsilometer (E) test on a blood agar plate. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) have no species specific breakpoints for C. diphtheriae, but the strain can be categorised as susceptible to benzylpenicillin according the EUCAST recommendations for non-species related clinical breakpoints [3].

Patient follow-up
After diagnosing C. diphtheriae infection on 25 March, and prior to obtaining the results of antimicrobial susceptibility testing, the treatment was changed from dicloxacillin to oral phenoxymethylpenicillin tablets 660 mg four times daily, according to the suggested regimens from The Sandford Guide To Antimicrobial Therapy 2014 [4]. The patient vaccination history was reviewed; he had completed the national childhood vaccination programme and received a diphtheria vaccine booster dose in 2005. The next day, on 26 March, the patient was admitted to Department of Infectious Diseases, St. Olavs Hospital, Trondheim, where he was isolated. He was afebrile and in good general health. There were no signs of pharyngeal involvement, C-reactive protein (CRP) was <5 mg/L (norm: 0–5 mg/L) and the leukocyte count was 9.1 x 109/L (norm: 3,7–10 x 109/L). An ulcerative, non-inflammatory wound was observed on his right big toe (Figure). He received intravenous benzylpenicillin treatment 1 million IU x 4, during the 24 hours hospitalisation and oral phenoxymethylpenicillin 660 mg two tablets three times daily for two weeks after discharge.

Figure. Ulcerative, non-inflammatory wound on the right big toe of a patient with cutaneous diphtheria, Norway, March 2014

Control measures and contact tracing

Immediately after diagnosing C. diphtheriae infection on 25 March, the case was reported by phone to the local Medical Officer in the municipality and NIPH in accordance with the Communicable Disease Act. In collaboration with the treating physician and the local Community Medical Officer, contact isolation precautions were implemented until the patient was admitted to the hospital. After discharge, he was isolated in his home until two control cultures (throat, nasal and wound swab) taken on 9 April and on 10 April and cultivated on Tinsdale selective medium, were negative on 15 April.

Tracing of close contacts was initiated on 25 March and oral erythromycin capsules 500 mg two times daily for seven days were given prophylactically. A booster diphtheria vaccine dose was offered to all contacts who received the last diphtheria vaccine dose more than five years prior and complete vaccination to those who had not been vaccinated in the primary childhood programme. Observation of close contacts in their homes (for fever, throat pain) in the following seven days after they had been exposed to the index patient was recommended. Throat and nasal specimens were also collected from these close contacts, which included 11 close family members, four friends and the primary examining physician. The specimens were cultivated, as well as patient control samples, on Tinsdale selective medium at St. Olavs Hospital, Trondheim; all were found negative for C. diphtheriae.

The index patient was attending the boarding school in Hurdal (located 70 km north of Oslo) and on his arrival to Norway, before he visited his family, the boarding school was the accommodation where he spent the first week of his vacation. During this week, the index patient and other schoolmates had eaten together in the kitchen of the boarding school and some of them had shared the bathrooms and sleeping rooms. Three other schoolmates, who had been working in Mozambique at the same time as the index patient, had also arrived to the boarding school. Taking this into consideration and according information obtained by local Medical Community Officer in Hurdal, throat and nasal specimens from 53 close contacts: 28 schoolmates and 25 other contacts – employees in the school and close contacts out of the boarding school –, were collected and sent to Akershus University Hospital in Oslo. All samples were cultivated on Tinsdale selective agar media (Tinsdale agar base, Oxoid product nr.CM 0487) and were found negative, except one throat swab from one of his schoolmates, a travel companion in Mozambique. This isolate was sent to NIPH and identified as C. diphtheriae biotype mitis by API Coryne v3 system (BioMérieux, France, code: 1010324) and supplementary tests. The isolate had the same biotype as the isolate from the index case, but differed by being lactose positive and toxin negative (both with tox gene PCR and modified Elek test).

This schoolmate, who had been working in Mozambique at the same orphanage as the index patient, may also have been infected during his stay there with another strain of C. diphtheriae, the non-toxigenic one, but was asymptomatic and discovered by screening. Molecular diagnostic that is planned in the near future, the genome sequencing of both isolates, should reveal if it was the identical strain infected by lysogenic tox phage in the index patient or two different strains.

After diagnosing C. diphtheriae throat colonisation, the vaccination history of the contact patient was reviewed; he had received a booster diphtheria vaccine dose in 2012 and was not offered a new one. He received the oral erythromycin capsules 500 mg two times daily for seven days and was isolated in the boarding school (separate room and bathroom), until two control throat specimens sampled at different times were negative. The vaccination history of the other 52 persons included in screening in Hurdal was reviewed and 29 close contacts who had been vaccinated more than five years prior received a booster diphtheria vaccine dose. All close contacts were given the oral erythromycin capsules 500 mg two times daily for seven days, with some exceptions (one pregnant woman and one child).

One of the schoolmates, who had also been working in Mozambique at the same time as others, had noticed skin ulcer on his leg, but in his case, the ulcer healed spontaneously and at the time of screening, the wound swab taken from the scar area was negative for C. diphtheriae.

Background and epidemiological situation

Diphtheria is caused by toxigenic strains of C. diphtheriae, C. ulcerans and C. pseudotuberculosis. It can result in an acute bacterial toxic infection of the upper respiratory tract or in cutaneous infection, which is generally a milder variant of the disease.

Cutaneous diphtheria is usually described as a chronic ulcer, often following insect bites or minor trauma. The incubation period is on average two to four days for respiratory tract diphtheria but is not so well defined for cutaneous infection. Immunised persons seldom develop systemic toxic manifestations and the slow absorption of toxin from skin lesions induces production of high antibody levels [5]. Isolation of C. diphtheriae by culture may be difficult due to normal throat or skin flora and other pathogens present; therefore selective media should be employed when diphtheria is suspected.

In reports from several European countries [6-9], isolates causing cutaneous diphtheria were mainly imported and toxigenic. Epidemiological control and vaccination are important measures in reducing the possibility of establishment of a reservoir for secondary transmission of both cutaneous and respiratory diphtheria [10].               

Diphtheria is rarely diagnosed in Norway due to high vaccine coverage. During the period from 1975 to 2013 only five cases of throat diphtheria or colonisation have been reported to the Norwegian Surveillance System for Communicable diseases (MSIS). In 1992, a young man from the county of Finnmark was infected after contact with a person from Russia. In 2008, a mother and her child were diagnosed with throat diphtheria after visiting Latvia. After their return to Norway, the father and one other child were infected [11,12].

A brief report of the present case has been covered in the bulletins of NIPH on 2 April 2014 as the first diagnosed toxigenic cutaneous diphtheria in Norway [13].           


Cutaneous diphtheria is endemic in some eastern European countries (Latvia, Russia) and many parts of the world (Brazil, Eastern Mediterranean region, Haiti, the Indian subcontinent, Indonesia, Nigeria and Philippines) [5] and physicians should be aware of the possibility of diphtheria in patients returning from visits/travel in endemic areas. C. diphtheriae can survive up to three months in floor dust [14] and in endemic areas with tropical climate this can be a likely source of infection/transmission.   

The report illustrates the importance of diagnosing diphtheria cases as soon as possible, given the amount of resources needed for subsequent contact-tracing and control measures, which is likely to increase when detection of an initial case is delayed. 

The diagnosis of diphtheria in the present case emphasises the importance of detailed clinical and epidemiological information given by the examining physician as well as access to modern diagnostic modalities. MALDI-TOF MS is easy to use, cost effective and enables rapid species identification in a couple of minutes [15]. The usefulness of MALDI-TOF MS as a tool for reliable C. diphtheriae identification was recently investigated by Konrad et al. [16]. They correctly identified to the species level all 90 potentially toxigenic Corynebacterium strains and proposed an algorithm for fast and reliable identification of C. diphtheriae incorporating MALDI-TOF MS, real-time tox PCR and Elek testing. This workflow was shown to be both rapid and effective in our case.   

The participation of laboratory in Trondheim in the United Kingdom National External Quality Assessment Service for Microbiology (UK NEQAS) also proved beneficial. One isolate of toxin-negative C. diphtheriae was recently distributed by UK NEQAS on 3 February 2014 (distribution nr.3361), and was successfully identified by MALDI TOF MS.

The collaboration of the laboratory in Trondheim with NIPH, performing the tox gene PCR, Elek testing, biotyping and susceptibility testing, and with the local Community Medical Officer, proved very efficient and optimal in the present case, when encountering a rare and potentially severe infectious disease. The contact patient diagnosed with non-toxigenic C. diphtheriae remained asymptomatic. Non-toxigenic strains of C. diphtheriae are recently recognised as emerging pathogens across Europe [17]. Such strains, however, can convert to toxigenicity by infection with lysogenic tox phage [18,19]. The circulation of resident non-toxigenic strains in the community thus can represent an ongoing risk by conversion to highly virulent strains following lysogenisation.          


The authors would like to thank the laboratory staff on the Department of Bacteriology and Infectious immunology, NIPH; in particular senior laboratory technologists Lene Haakensen and Gunnhild Rødal for performing the Elek and biochemical phenotypic identification, and Veronika Klausmark Jensen for performing the tox gene PCR. We gratefully acknowledge the skilful work by laboratory staff at the Department of Medical microbiology, St. Olavs Hospital; in particular microbiology technologists Ann Helland, Silje Mari Nilsen Reinfjell and Marit Gaustad, MD/Microbiologist Kjersti Wik Larssen and MD/resident in Medical microbiology Nicola Isabelle Kols.
Thanks to Anne Stine Garnes, MD, Community Medical Officer in Hurdal, for epidemiological survey in boarding school in Hurdal, attended by the index case.
Thanks to laboratory staff on the Department of Bacteriology, Akershus University Hospital in Oslo; in particular MD/Microbiologists Veselka Petrova Dimova Svetoslavova and Truls Michael Leegaard. 

Conflict of interest
None declared.

Authors’ contributions
Wrote the manuscript: AJ, MS, ATM, PBS, ES, TS, KR, HB, KB; performed clinical investigations: PBS, TS; performed laboratory investigations: AJ, MS, ATM, HB, KB; performed epidemiological investigations: ES, KR, HB.



  1. Schuhegger R, Lindermayer M, Kugler R, Heesemann J, Busch U, Sing A. Detection of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans Strains by a Novel Real-Time PCR. J. Clin. Microbiol. 2008;46(8):2822-3.
  2. Engler KH, Glushkevich T, Mazurova IK, George RC, Efstratiou A. A modified Elek test for detection of toxigenic corynebacteria in the diagnostic laboratory. J. Clin. Microbiol. 1997;35(2):495-8.
  3. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters; version 4.0. Växjö: EUCAST. 1 Jan 2014. Available from:
  4. Gilbert DN, Chambers HF, Eliopoulos GM. The Sanford Guide To Antimicrobial Therapy 2014. 44th ed. Sperryville: Antimicrobial Therapy; 2014.
  5. Mandell GI, Bennett JE, Dolin R. Mandell, Douglas and Bennett`s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. pp. 2687-93.
  6. de Benoist AC, White JM, Efstratiou A, Kelly C, Mann G, Nazareth B, et al. Imported Cutaneous Diphtheria, United Kingdom. Emerg Infect Dis. 2004; 10(3):.511-3.
  7. Sing A, Heesemann J. Imported Cutaneous Diphtheria, Germany, 1997-2003. Emerg Infect Dis. 2005;11(2):343-4.
  8. Rousseau C, Belchior E, Broche B, Badell E, Guiso N, Laharie I, et al. Diphtheria in the south of France, March 2011. Euro Surveill. 2011;16(19):pii=19867.
  9. Lindhusen-Lindhé E, Dotevall L, Berglund M. Imported laryngeal and cutaneous diphtheria in tourists returning from western Africa to Sweden, March 2012. Euro Surveill. 2012;17(23):pii=20189.
  10. Neal S, Efstratiou A. DIPNET, -establishment of a dedicated surveillance network for diphtheria in Europe. Euro Surveill. 2007;12(12):pii=754.
  11. Rasmussen I, Wallace S, Mengshoel AT, Høiby EA, Brandtzæg P. Diphtheria outbreak in Norway: Lessons learned. Scand J Infect Dis. 2011;43(11-12):986-9.
  12. Blystad H. Smittevernboka. Difteri. March 2014. Oslo: Folkehelseinstitutt. Norwegian. Available from:
  13. Folkehelseinstitutt. Huddifteritilfelle på Østlandet. Oslo: Folkehelseinstitutt. Norwegian. Available from:
  14. Crosbie WE, Wright HD. Diphtheria bacilli in floor dust. Lancet. 1941;237(6143): 656-9.
  15. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, et al. Ongoing revolution in bacteriology: Routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009;49(4):543-51.
  16. Konrad R, Berger A, Huber I, Boschert V, Hörmansdorfer S, Busch U, et al. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry as a tool for rapid diagnosis of potentially toxigenic Corynebacterium species in the laboratory management of diphtheria-associated bacteria. Euro Surveill. 2010;15(43):pii=19699.
  17. Funke G, Altwegg M, Frommelt L, von Graevenitz A. Emergence of related nontoxigenic Corynebacteirum diphtheriae biotype mitis strains in Western Europe. Emerg Infect Dis. 1999:5(3):477-80.
  18. Zakikhany K, Neal S, Efstratiou A. Emergence and molecular characterisation of non-toxigenic tox gene-bearing Corynebacterium diphtheriae biovar mitis in the United Kingdom, 2003-2012. Euro Surveill. 2014:19(22):pii=20819.
  19. Pappenheimer AM Jr, Murphy JR. Studies on the molecular epidemiology on diphtheria. Lancet. 1983;322(8356): 923-6.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.